혈당 모니터링 시장 - 세계 예측(2026-2032년)

The Blood Glucose Monitoring Market is projected to grow by USD 27.23 billion at a CAGR of 8.61% by 2032.

Blood Glucose Monitoring Executive Summary

Blood glucose monitoring has become a critical pillar of diabetes management as health systems respond to the rising global burden of diabetes, prediabetes, obesity, and cardiometabolic disease. The category includes self-monitoring blood glucose devices, continuous glucose monitoring systems, lancets, test strips, sensors, transmitters, connected meters, mobile applications, and integrated digital care platforms. Its clinical value is anchored in helping people with diabetes understand glycemic patterns, reduce hypo- and hyperglycemic events, support insulin dosing decisions, and improve day-to-day disease management in consultation with healthcare professionals.

Demand is being shaped by the shift from episodic fingerstick testing toward more continuous, personalized, and data-driven glucose insights. Regulatory clearances for factory-calibrated sensors, broader reimbursement in several countries, remote patient monitoring adoption, and stronger clinical evidence supporting time-in-range metrics are increasing the relevance of glucose monitoring across type 1 diabetes, insulin-treated type 2 diabetes, gestational diabetes, and selected high-risk populations. At the same time, affordability, accuracy, interoperability, skin tolerability, data privacy, and equitable access remain core industry challenges.

For stakeholders, the blood glucose monitoring landscape is no longer defined only by device performance. It is increasingly shaped by connected care ecosystems, real-world evidence, patient engagement, artificial intelligence-enabled analytics, and integration with insulin delivery, telehealth, electronic health records, and population health programs.

Transformative Shifts in the Blood Glucose Monitoring Landscape

The blood glucose monitoring landscape is undergoing a structural transition from reactive testing to proactive glycemic intelligence. Traditional self-monitoring remains essential, particularly for affordability-sensitive settings and for patients who require periodic glucose checks; however, continuous glucose monitoring is redefining clinical workflows by providing trend arrows, alerts, time-in-range data, and retrospective pattern analysis. This evolution is changing the role of monitoring from a standalone measurement activity into an always-on feedback loop for patients, caregivers, and clinicians.

A major shift is the movement toward consumer-friendly and minimally burdensome devices. Smaller sensors, longer wear durations, simplified insertion, Bluetooth connectivity, and smartphone-based dashboards are improving adherence and usability. In parallel, clinical practice is increasingly emphasizing actionable metrics such as time in range, glycemic variability, and nocturnal hypoglycemia rather than relying only on isolated glucose values or periodic glycated hemoglobin testing. These metrics support more individualized treatment adjustments and are particularly relevant for insulin users.

Healthcare delivery models are also changing. Remote monitoring programs, virtual endocrinology visits, pharmacist-led diabetes care, and payer-supported chronic disease management are expanding the points of care where glucose data can be used. In hospitals, glucose monitoring protocols are being refined for critical care, perioperative management, and inpatient diabetes safety. Meanwhile, regulatory expectations continue to focus on accuracy standards, cybersecurity, human factors, clinical validation, and post-market performance, encouraging manufacturers and digital health partners to prioritize reliability and transparency.

The most consequential industry transformation is the convergence of diagnostics, therapeutics, and digital health. Blood glucose monitoring is becoming linked with insulin pumps, smart insulin pens, decision-support software, nutrition coaching, physical activity tracking, and behavioral interventions. This convergence is improving patient-centered care but also raising new requirements for interoperable data formats, device-agnostic platforms, reimbursement evidence, and responsible use of personal health information.

Cumulative Impact of Artificial Intelligence on Blood Glucose Monitoring

Artificial intelligence is amplifying the value of blood glucose monitoring by converting large volumes of glucose readings into clinically relevant insights. Continuous glucose monitoring produces dense time-series data that can be analyzed to detect patterns, predict glycemic excursions, identify overnight hypoglycemia risk, and support personalized recommendations. AI-enabled analytics can help stratify patients by risk, flag deteriorating control, and assist clinicians in prioritizing interventions for individuals who need timely support.

The cumulative impact of AI is most visible in decision support. Algorithms can combine glucose trends with insulin dosing records, meal timing, physical activity, sleep patterns, illness indicators, and medication changes to generate context-aware insights. In closed-loop and automated insulin delivery systems, algorithmic control is central to adjusting insulin delivery in response to changing glucose levels. In remote care, AI can reduce clinician burden by summarizing complex data, highlighting outliers, and creating concise reports that support faster, evidence-informed consultations.

AI is also influencing product development and quality management. Machine learning can support sensor signal processing, noise reduction, calibration optimization, anomaly detection, and post-market surveillance. For population health programs, predictive analytics can identify cohorts at elevated risk of acute complications or poor adherence, enabling targeted education and outreach. However, adoption depends on robust clinical validation, explainability, bias mitigation, cybersecurity, consent management, and alignment with medical device software regulations.

The most durable AI opportunity in blood glucose monitoring lies in augmenting, not replacing, clinical judgment and patient self-management. Systems that deliver clear, safe, personalized, and actionable recommendations are more likely to gain trust from healthcare professionals, payers, and patients. As evidence requirements rise, stakeholders must demonstrate that AI-enabled glucose monitoring improves measurable outcomes such as time in range, hypoglycemia reduction, therapy adherence, care efficiency, and patient quality of life.

Key Regional Insights for Blood Glucose Monitoring

Asia-Pacific is a central growth engine for blood glucose monitoring because of its high diabetes burden, rapid urbanization, changing diets, aging populations, and expanding digital health infrastructure. China and India have large populations living with diabetes, creating strong demand for accessible glucose testing, connected meters, and scalable diabetes management programs. Japan, South Korea, and Australia show stronger adoption of advanced continuous glucose monitoring and connected care due to mature healthcare systems, structured reimbursement pathways, and high digital literacy. Across Southeast Asia, the environment is shaped by uneven access, out-of-pocket spending, and rising policy attention to noncommunicable disease prevention.

North America remains a leading region for advanced blood glucose monitoring adoption, supported by established diabetes care guidelines, specialist networks, remote patient monitoring capabilities, and broad familiarity with continuous glucose monitoring among insulin-treated patients. The United States has seen increasing integration of glucose data with telehealth, automated insulin delivery, pharmacy-based care, and value-based chronic disease programs, while Canada emphasizes evidence-based coverage decisions, provincial reimbursement variation, and equitable access for insulin users and pediatric populations.

Latin America presents a mixed access environment. Urban centers in Brazil, Mexico, and other larger economies increasingly use connected glucose meters and selected continuous monitoring technologies, but affordability, reimbursement gaps, and public health system capacity influence adoption. Diabetes prevalence, obesity, and delayed diagnosis continue to drive clinical need, while public-private initiatives, pharmacy channels, and physician education are important routes for improving monitoring frequency and patient engagement.

Europe is shaped by strong clinical governance, reimbursement evaluation, and data protection standards. Countries such as Germany, France, the United Kingdom, Italy, and Spain have incorporated glucose monitoring into structured diabetes care pathways, with increasing attention to continuous glucose monitoring for type 1 diabetes, insulin-intensive type 2 diabetes, pregnancy-related diabetes management, and pediatric care. The region's regulatory environment supports high standards for safety, performance, interoperability, and privacy, while healthcare budget pressures require strong real-world evidence.

The Middle East is experiencing rising demand due to high diabetes prevalence in Gulf countries, urban lifestyles, and significant investment in digital health and specialty care. Adoption is strongest in higher-income health systems that support specialist-led diabetes programs and connected care, while broader regional access varies by reimbursement, public procurement, and private insurance coverage. Africa faces a different set of challenges, including underdiagnosis, limited access to testing supplies, affordability constraints, and uneven laboratory and primary care infrastructure. Nevertheless, mobile health, community-based screening, and lower-cost self-monitoring solutions are important pathways for expanding glucose monitoring access across the continent.

Key Group Insights for Blood Glucose Monitoring

ASEAN countries are experiencing increasing demand for blood glucose monitoring as diabetes prevalence rises alongside urbanization, sedentary behavior, and dietary changes. The region includes highly developed healthcare systems as well as markets with significant out-of-pocket expenditure, making affordability and distribution critical. Connected meters, pharmacy-led testing, primary care screening, and gradual adoption of continuous glucose monitoring are shaping the regional pathway, especially where digital health policy and private insurance coverage are advancing.

The GCC is one of the most clinically important groups for diabetes care because Gulf countries report a substantial cardiometabolic disease burden and invest heavily in modern healthcare infrastructure. Blood glucose monitoring adoption benefits from specialist diabetes centers, government health initiatives, private insurance, and strong interest in digital health transformation. Continuous glucose monitoring, remote monitoring, and integrated diabetes care models are increasingly relevant, particularly for insulin-treated patients and high-risk populations.

The European Union emphasizes regulated, evidence-based, and privacy-conscious adoption of blood glucose monitoring technologies. Harmonized medical device regulations, health technology assessment processes, and strict data protection requirements influence product development, access, and clinical deployment. Within the EU, reimbursement policies differ by member state, but the overarching trend favors clinically validated monitoring tools that improve safety, support self-management, and integrate with broader chronic disease care.

BRICS countries represent a diverse and high-need environment for blood glucose monitoring. China, India, Brazil, Russia, and South Africa face rising diabetes burdens, but differ significantly in healthcare financing, urban-rural access, domestic manufacturing capacity, and digital health maturity. Cost-effective self-monitoring, scalable connected devices, and public health programs are crucial, while advanced continuous glucose monitoring adoption is more concentrated among insured, urban, and specialist-managed patient groups.

G7 countries generally lead in clinical adoption, regulatory maturity, reimbursement evaluation, and integration of blood glucose monitoring into digital care pathways. These countries are important reference markets for evidence generation, safety standards, interoperability expectations, and real-world performance assessment. Aging populations, insulin-treated type 2 diabetes, pediatric diabetes care, and remote monitoring are key drivers of continued technology use.

NATO member countries overlap with several high-income diabetes care markets in North America and Europe, but the group also includes health systems with varied reimbursement and infrastructure levels. Across these countries, blood glucose monitoring is influenced by chronic disease strategies, digital health modernization, supply chain resilience, cybersecurity requirements, and public procurement standards. Military and veteran healthcare systems also underscore the importance of reliable monitoring, chronic disease continuity, and secure health data exchange.

Key Country Insights for Blood Glucose Monitoring

The United States is one of the most advanced blood glucose monitoring markets, driven by clinical guideline adoption, continuous glucose monitoring reimbursement expansion, remote patient monitoring, and integration with automated insulin delivery. Canada shows strong clinical use but with provincial differences in coverage and access, making reimbursement policy a key determinant of adoption. Mexico's demand is supported by a large diabetes burden, yet affordability and fragmented access shape monitoring behavior.

Brazil is Latin America's most prominent diabetes care environment, with growing use of glucose monitoring in urban private healthcare and public health programs, although cost and access remain major considerations. The United Kingdom has emphasized structured diabetes care through national health pathways, with increasing availability of continuous glucose monitoring for eligible groups and strong attention to clinical evidence. Germany combines high healthcare capacity, medical device regulation, and reimbursement mechanisms that support advanced monitoring where evidence is compelling.

France maintains a clinically governed approach to diabetes technologies, with reimbursement tied to defined patient eligibility and outcome evidence. Russia has significant diabetes care needs across a large geography, where access to supplies, regional healthcare capacity, and procurement policies influence monitoring use. Italy and Spain are shaped by aging populations, strong specialist care networks, and regional healthcare administration, with continuous glucose monitoring adoption supported by clinical guidelines and localized reimbursement pathways.

China has a very large population affected by diabetes and is expanding access through hospital care, digital health adoption, domestic device development, and chronic disease management programs. India has one of the world's largest diabetes populations, making affordability, primary care reach, mobile health, and preventive screening central to glucose monitoring expansion. Japan's mature healthcare system, aging population, and technology acceptance support sophisticated diabetes management, including connected and continuous monitoring for appropriate patient groups.

Australia benefits from organized diabetes care, public subsidy mechanisms, and high adoption of digital health tools, particularly for eligible type 1 diabetes and insulin-treated patients. South Korea combines advanced healthcare infrastructure, strong digital connectivity, and growing attention to chronic disease management, supporting adoption of connected meters, continuous glucose monitoring, and integrated data-driven care models.

Actionable Recommendations for Blood Glucose Monitoring Leaders

Industry leaders should prioritize clinically meaningful innovation that improves accuracy, usability, affordability, and adherence. Devices must be designed for real-world use across age groups, skin types, digital literacy levels, and care settings. Reducing sensor burden, improving wear comfort, extending sensor life, simplifying onboarding, and minimizing data overload can enhance patient experience and persistence.

Evidence generation should be central to strategy. Stakeholders need robust clinical studies and real-world evidence demonstrating improvements in time in range, hypoglycemia prevention, therapy optimization, patient satisfaction, and care efficiency. Payers and health systems increasingly require proof that glucose monitoring technologies improve outcomes and reduce avoidable complications.

Interoperability should be treated as a strategic requirement. Blood glucose monitoring solutions should integrate securely with insulin pumps, smart pens, electronic health records, telehealth platforms, pharmacy care systems, and population health dashboards. Open standards, clear data governance, and cybersecurity-by-design will be essential for trust and scalability.

Access strategies must be tailored by region. In high-income markets, leaders should focus on reimbursement evidence, digital integration, and AI-enabled care workflows. In middle- and lower-income markets, affordability, distribution partnerships, local education, durable supply chains, and lower-cost monitoring options are critical. Patient and clinician education should remain a continuous investment to ensure glucose data translates into better self-management and safer treatment decisions.

Research Methodology for Blood Glucose Monitoring Analysis

This executive summary is developed using a structured secondary and primary research approach focused on verified, data-backed insights while excluding market sizing, market share, and forecasting. The methodology draws on publicly available clinical guidelines, regulatory documentation, peer-reviewed literature, diabetes epidemiology resources, reimbursement policies, health technology assessment publications, product safety standards, and recognized public health databases.

The research framework evaluates the blood glucose monitoring ecosystem across technology type, clinical application, end-user setting, regulatory environment, reimbursement context, digital health integration, and regional access dynamics. Evidence is cross-validated through triangulation across multiple credible sources to reduce bias and ensure consistency. Particular attention is given to diabetes burden, clinical adoption patterns, continuous glucose monitoring evidence, self-monitoring use cases, AI-enabled analytics, interoperability, cybersecurity, and health equity considerations.

Primary insight development incorporates expert-oriented interpretation of healthcare delivery trends, payer requirements, clinician workflows, patient behavior, and policy developments. Regional, group, and country analysis is synthesized into narrative insights to reflect how infrastructure, reimbursement, affordability, clinical guidelines, and digital maturity shape blood glucose monitoring adoption. The result is an SEO-optimized, decision-ready view of the sector that supports strategic planning without relying on speculative estimates or forecasts.

Conclusion

Blood glucose monitoring is evolving from a measurement-based device category into an integrated, data-driven diabetes management ecosystem. Continuous glucose monitoring, connected self-monitoring devices, remote care platforms, AI-enabled analytics, and interoperable digital health systems are reshaping how patients and clinicians manage glycemic control. The strongest opportunities are tied to technologies that deliver accurate, affordable, actionable, and secure insights while fitting naturally into daily life and clinical workflows.

Regional and country dynamics show that adoption is highly dependent on reimbursement, affordability, healthcare infrastructure, clinical education, and digital readiness. High-income markets are advancing toward integrated and automated diabetes care, while emerging markets require scalable, cost-effective solutions that expand access to essential monitoring. Across all settings, the need for evidence-based care, patient-centered design, and responsible data use remains paramount.

Industry participants that align innovation with clinical outcomes, equitable access, regulatory expectations, and digital interoperability will be best positioned to support the next phase of diabetes care. The future of blood glucose monitoring will be defined by trusted technologies that help people understand glucose patterns, prevent acute events, personalize therapy, and improve long-term health outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Blood Glucose Monitoring Market, by Product Type

• 7.1. Introduction
• 7.2. Continuous Glucose Monitoring Systems
  • 7.2.1. Intermittently Scanned Systems
  • 7.2.2. Real Time Continuous Systems
• 7.3. Self Monitoring Devices
  • 7.3.1. Control Solutions
  • 7.3.2. Glucose Meters
  • 7.3.3. Lancing Devices
  • 7.3.4. Test Strips

8. Blood Glucose Monitoring Market, by Modality

• 8.1. Introduction
• 8.2. Invasive Monitoring
• 8.3. Minimally Invasive Monitoring

9. Blood Glucose Monitoring Market, by Application

• 9.1. Introduction
• 9.2. Type 1 Diabetes
• 9.3. Type 2 Diabetes

10. Blood Glucose Monitoring Market, by End User

• 10.1. Introduction
• 10.2. Ambulatory Care
• 10.3. Diagnostic Laboratories
• 10.4. Home Care
• 10.5. Hospitals

11. Blood Glucose Monitoring Market, by Distribution Channel

• 11.1. Introduction
• 11.2. Offline
• 11.3. Online

12. Blood Glucose Monitoring Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Blood Glucose Monitoring Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Blood Glucose Monitoring Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. Acon Laboratories, Inc.
• 16.3. Advin Health Care
• 16.4. ARKRAY, Inc.
• 16.5. B. Braun Melsungen AG
• 16.6. Becton, Dickinson and Company
• 16.7. Bioland Technology Ltd.
• 16.8. Dexcom, Inc.
• 16.9. F. Hoffmann-La Roche Ltd.
• 16.10. ForaCare Inc.
• 16.11. GlySens Incorporated
• 16.12. I-SENS, Inc.
• 16.13. Insulet Corporation
• 16.14. LifeScan IP Holding, LLC
• 16.15. Medtronic PLC
• 16.16. Medtrum Technologies Inc.
• 16.17. Nemaura Medical Inc.
• 16.18. Nipro Europe Group Companies
• 16.19. Nova Biomedical
• 16.20. PHC Holding Corporation
• 16.21. Prodigy Diabetes Care LLC
• 16.22. Senseonics Holdings Inc.
• 16.23. Sinocare Inc.
• 16.24. Terumo Corporation